Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen non-GAAP Cost of Sales ($M) ($M)
Form 8-K Reconciliations of GAAP to Non-GAAP Measures
Latest, FY2025
6,423
Period ended Dec 31, 2025
Change on a year earlier
+12.0%
5,736 in FY2024
History
9 years
Since FY2017
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Non-GAAP Cost of Sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6,423 | +12.0% | Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 5,736 | +25.4% | Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 4,573 | +15.7% | Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗ |
| FY2022 | Dec 31, 2022 | 3,951 | -1.1% | Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗ |
| FY2021 | Dec 31, 2021 | 3,994 | +18.8% | Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗ |
| FY2020 | Dec 31, 2020 | 3,362 | +9.7% | Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗ |
| FY2019 | Dec 31, 2019 | 3,065 | +2.1% | Form 8-K (amgn-20191231xq4ex991.htm, filed 2020-01-30) ↗ |
| FY2018 | Dec 31, 2018 | 3,001 | +2.0% | Form 8-K (amgn-20181231xq4exhibit991.htm, filed 2019-01-29) ↗ |
| FY2017 | Dec 31, 2017 | 2,943 | – | Form 8-K (amgn-20181231xq4exhibit991.htm, filed 2019-01-29) ↗ |
Breakdown
What makes up non-gaap cost of sales ($m)
Cite this data
StockData. (2026). Amgen Non-GAAP Cost of Sales ($M) ($M), annual FY2017–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/ng_cogs
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.